Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.
The first ciprofloxacin containing product was FDA approved on 22 October 1987.
Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...
Mount Sinai Hospital, Toronto, Ontario, Canada
University of Wisconsin, Madison, Wisconsin, United States
Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, Paris, France
University of Miami Miller School of Medicine, Miami, Florida, United States
University of Washington, Seattle, Washington, United States
International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Nagoya University Graduate School of Medicine, Nagoya, Japan
Sint Antonius Hospital, Nieuwegein, Utrecht, Netherlands
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Providence Hospital - Southfield, Southfield, Michigan, United States
Mary Crowley Medical Research Center, Dallas, Texas, United States
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.